PTC Therapeutics Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
PTC Therapeutics Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
PTC Therapeutics, Inc. (NASDAQ:PTCT) shareholders may have reason to be concerned, as several insiders sold their shares over the past year. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
PTC Therapeutics, Inc. (NASDAQ:PTCT)的股東們可能有理由擔心，因爲過去一年中有幾位內部人士出售了他們的股票。分析內部交易時，了解內部人士是買入還是賣出通常更有價值，因爲後者傳遞出了一種模棱兩可的信息。然而，當多個內部人士在一段特定的時間內出售股票時，股東應該注意，因爲這可能是一個警告信號。
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
雖然我們不認爲股東應該簡單地跟隨內部交易，但完全忽略內部交易將是愚蠢的。
The Last 12 Months Of Insider Transactions At PTC Therapeutics
過去12個月內的PTC Therapeutics內部交易
Over the last year, we can see that the biggest insider sale was by the CEO & Director, Matthew Klein, for US$274k worth of shares, at about US$27.15 per share. That means that an insider was selling shares at slightly below the current price (US$33.99). When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. It is worth noting that this sale was only 23% of Matthew Klein's holding.
在過去的一年裏，我們可以看到最大的內部人士出售是由首席執行官兼董事Matthew Klein進行的，價值爲27.4萬美元，每股價格約爲27.15美元。這意味着內部人士以略低於當前價格（33.99美元）的價格出售股票。當內部人士以低於當前價格出售股票時，這表明他們認爲較低的價格是公平的。這讓我們想知道他們對（更高的）最近估值有什麼看法。然而，儘管內部人士的賣出有時令人沮喪，但這只是一個弱信號。值得注意的是，這次銷售只佔了Matthew Klein所持股份的23%。
All up, insiders sold more shares in PTC Therapeutics than they bought, over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
總體而言，過去一年內，PTC Therapeutics的內部人士賣出的股票比買入的股票多。您可以在下面的圖表中看到過去一年內的內部交易（通過公司和個人）。如果您想了解到底是誰賣出的，以及以什麼價格和何時賣出，請點擊下面的圖表！
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
對於那些喜歡發現潛力股票的人，可以免費查看最新內部交易股票的小盤公司名單，這可能正是您要找的機會。
Insiders At PTC Therapeutics Have Sold Stock Recently
PTC Therapeutics的內部人士最近賣出了股票
The last three months saw significant insider selling at PTC Therapeutics. In total, Chief Financial Officer Pierre Gravier sold US$77k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.
在過去的三個月裏，PTC Therapeutics的內部人士大量賣出股票。總的來說，首席財務官Pierre Gravier在這段時間內出售了7.7萬美元的股票，而我們沒有記錄到任何購買。鑑於此，很難說所有內部人士都認爲這些股票是便宜貨。
Insider Ownership Of PTC Therapeutics
PTC Therapeutics的內部所有權
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. PTC Therapeutics insiders own about US$61m worth of shares. That equates to 2.3% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
測試公司領導與其他股東之間的一致性的另一種方法是查看他們擁有的股份數量。如果內部人士在公司中擁有相當數量的股份，我認爲這是一個好跡象。PTC Therapeutics的內部人士擁有價值6100萬美元的股份，佔公司的2.3%。這種內部人士的持股比例很好，但並不特別突出。這確實表明了一個合理的一致程度。
So What Does This Data Suggest About PTC Therapeutics Insiders?
那麼，這些數據對PTC Therapeutics的內部人士有什麼意義呢？
An insider hasn't bought PTC Therapeutics stock in the last three months, but there was some selling. Zooming out, the longer term picture doesn't give us much comfort. Insiders own shares, but we're still pretty cautious, given the history of sales. We're in no rush to buy! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. When we did our research, we found 3 warning signs for PTC Therapeutics (1 is potentially serious!) that we believe deserve your full attention.
最近三個月內，沒有內部人士買入PTC Therapeutics的股票，但有一些賣出。從更長期的圖景來看，我們並沒有得到很多安慰。雖然內部人士擁有股份，但考慮到賣出的歷史，我們仍然非常謹慎。我們不急着買入！因此，這些內部交易可以幫助我們建立關於這支股票的論點，但了解這家公司面臨的風險也是值得的。在我們進行調研時，我們發現了PTC Therapeutics的3個預警信號（其中1個可能非常嚴重！）我們認爲這些值得您的充分注意。
Of course PTC Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然，PTC Therapeutics可能並不是最好的股票可供購買。因此，您可能希望查看這些高質量公司的免費合集。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。